Stem Cell Therapy for Pediatric Dilated Cardiomyopathy

Ischemic Heart Disease (D Mukherjee, Section Editor)

DOI: 10.1007/s11886-013-0369-z

Cite this article as:
Selem, S.M., Kaushal, S. & Hare, J.M. Curr Cardiol Rep (2013) 15: 369. doi:10.1007/s11886-013-0369-z
Part of the following topical collections:
  1. Topical Collection on Ischemic Heart Disease


Dilated cardiomyopathy is a serious and life-threatening disorder in children. It is the most common form of pediatric cardiomyopathy. Therapy for this condition has varied little over the last several decades and mortality continues to be high. Currently, children with dilated cardiomyopathy are treated with pharmacological agents and mechanical support, but most require heart transplantation and survival rates are not optimal. The lack of common treatment guidelines and inadequate survival rates after transplantation necessitates more therapeutic clinical trials. Stem cell and cell-based therapies offer an innovative approach to restore cardiac structure and function towards normal, possibly reducing the need for aggressive therapies and cardiac transplantation. Mesenchymal stem cells and cardiac stem cells may be the most promising cell types for treating children with dilated cardiomyopathy. The medical community must begin a systematic investigation of the benefits of current and novel treatments such as stem cell therapies for treating pediatric dilated cardiomyopathy.


Pediatric dilated cardiomyopathy Idiopathic dilated cardiomyopathy Pediatric congestive heart failure Stem cells Cell based therapy Bone marrow stem cells Mesenchymal stem cells Cardiac stem cells 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sarah M. Selem
    • 1
  • Sunjay Kaushal
    • 2
  • Joshua M. Hare
    • 1
  1. 1.Interdisciplinary Stem Cell InstituteUniversity of Miami Miller School of MedicineMiamiUSA
  2. 2.Division of Cardiac SurgeryUniversity of Maryland Medical CenterBaltimoreUSA

Personalised recommendations